

Phase I trial, Quotient Code: QSC300414

Submission date 05/05/2023	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 09/05/2023	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 09/05/2023	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Nand Singh

Contact details

Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 303 1000
Recruitment@weneedyou.co.uk

Type(s)

Scientific

Contact name

Dr Fabrizio Giordanetto

Contact details

120 West 45th Street
39th Floor
New York

United States of America
NY 10036
+1 (0) 212 849 0880
Fabrizio.Giordanetto@DEShawResearch.com

Type(s)

Public

Contact name

Dr Fabrizio Giordanetto

Contact details

120 West 45th Street
39th Floor
New York
United States of America
NY 10036
+1 (0) 212 849 0880
Fabrizio.Giordanetto@DEShawResearch.com

Additional identifiers

Integrated Research Application System (IRAS)

1007622

Protocol serial number

Quotient Code: QSC300414

Study information

Scientific Title

Phase I trial, Quotient Code: QSC300414 [The full scientific title will be published within 30 months after the end of the trial]

Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Submitted 18/04/2023, HSC REC B (ORECNI, Business Services Organisation, Lissue Industrial Estate West, Lisburn, Co. Antrim BT28 2RF, Northern Ireland, UK; +44 (0)28 9536 1400; recb@hscni.net), ref: 23/NI/0043
2. Submitted 18/04/2023, MHRA (10 South Colonnade, Canary Wharf, London E14 4PU, UK; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 57954/0001/001-0001

Study design

Two-part single-center double-blind randomized study to assess PK, safety and tolerability in 104 healthy volunteers

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

24/03/2024

Eligibility

Key inclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

27/06/2023

Date of final enrolment

14/03/2024

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Quotient Sciences Limited**

Mere Way

Ruddington Fields

Ruddington

Nottingham

United Kingdom

NG11 6JS

Sponsor information**Organisation**

D. E. Shaw Research

ROR

<https://ror.org/02s04h872>

Funder(s)

Funder type

Industry

Funder Name

D. E. Shaw Research

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available